
News|Videos|September 21, 2023
Data From FLAURA2: Osimertinib With or Without Chemotherapy in Metastatic NSCLC
Expert Stephen Liu, MD, joins the Oncology Brothers to share insight into updated data from the FLAURA2 trial of osimertinib with or without chemotherapy in patients with metastatic non–small cell lung cancer.
Advertisement
Episodes in this series

Now Playing
Advertisement
Related Content




Divarasib Improves Survival Vs Approved KRAS G12C Inhibitors in NSCLC
Published: | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma
2
FDA Approves Perioperative Pembrolizumab Plus Enfortumab Vedotin for MIBC
3
Osimertinib After Chemoradiotherapy Shows Manageable Safety in NSCLC
4
First Patient Treated With PSMA-Targeted Actinium-225 Alpha Emitter in mCRPC
5




































